patients treated according to national practice guidelines have better clinical outcomes than those who weren't? In this study, the authors evaluated differences in clinical outcomes between women undergoing adjuvant treatment for breast cancer whose treatment adhered 100 % to German national practice guidelines, and women whose treatments plans did not conform 100 % to these guidelines. The different therapeutic modalities evaluated here included surgical therapy, radiotherapy, adjuvant endocrine therapy, and adjuvant chemotherapy.
This analysis was done separately for women treated before and after the year 2000. The authors compared outcomes between two different time intervals 1991-2000 (TI1) and 2001 -2009 . In these subgroups, the risk of recurrence (RFS) and overall survival (OS) were compared between patients whose treatment was either conformed 100 % to national practice guidelines, or non-guideline conforming. Interestingly, the authors found that in women who received 100 % guideline-conforming therapy, both OS and RFS were significantly improved compared with patients who were not treated in accordance with clinical guidelines (RFS: p \ 0.001, HR = 0.51, 95 % CI 0.44-0.59; OS: p \ 0.001, HR = 0.46, 95 % CI 0.40-0.53). They also reported that clinical outcomes from TI1 to TI2 improved even for patients whose treatment was non-guideline adherent. The authors then conclude from this that clinical guidelines are not clinically ''advantageous'' in improving clinical outcomes among breast cancer patients. However, in quality terms, the data presented in this paper show quite convincingly that at least in patients treated 100 % according to national guidelines clinical outcomes did improve, presumably though a reduction in the variation of care. Patients treated on pathway did better than those who were not. The fact that even breast cancer patients whose care was not 100 % adherent to evidence-based practice guidelines had measurable improvements in clinical outcomes does not mean that guidelines are ineffective. Quite the contrary, this improvement in outcomes occurred precisely because of advances in breast cancer care. The authors used an impossibly high standard of adherence-anything short of 100 % adherence to evidence-based guidelines was considered non-adherent in this analysis. That means, even in patients that were treated in a manner that was 80 % adherent with evidence-based guidelines their treatment was classified as non-adherent. So it is not surprising then that even patients in the non-adherent group did better over time, because most of these patients were likely treated in some degree according to evidence-based guidelines. Even if they were not treated 100 % according to practice guidelines, some of their care was likely guideline adherent.
A 100 % adherence standard for clinical guidelines is an impossible standard to expect from both patients and clinicians. Too much adherence to guidelines is not necessarily good, and would stifle medical innovation. Some other reasonable level of adherence to medical guidelines should be expected.
One of the major unanswered questions of this study was that it did not explore why breast cancer patients were not treated according to national guidelines by their oncologists. In other words, what were the factors behind non-adherence? Were there any discernible patterns on the doctor side as to who was not practicing according to national guidelines? Implementation and dissemination of evidence-based guidelines into routine practice is difficult, due to a variety of many different factors which are well described in the literature [7] [8] [9] [10] [11] .
Therefore, understanding why certain guidelines were or were not followed would ideally help to build better systems to enhance adherence among physicians. Finally, when it comes to following evidence-based guidelines, physicians are only half of the equation. We all know that many times the best available evidence may not apply to an individual patient. There are also many patient-driven factors which clearly can have a major impact on adherence to evidence-based guidelines, e.g., socio-economic factors, beliefs, and preferences. Regardless of the reasons-patient or physician related-for non-adherence to guidelines, this study demonstrated rather convincingly that clinical outcomes of breast cancer patients were significantly improved by practicing evidence-based medicine. And, as the U.S. health care system rapidly accelerates toward a pay for performance model, studies like this one are evidence that we are moving in the right direction.
